Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company.
Lymphoma maintenance therapy delivers promise in CTCL europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has randomised the first idiopathic intracranial hypertension (IIH) patient into its IIH Evolve Phase III clinical trial using lead drug Presendin.
PTA-News: 4SC AG: 4SC gibt Umsetzung der angekündigten Aktienzusammenlegung im Verhältnis 5:1 bekannt finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
4SC AG: 4SC & NKI kooperieren bei der klinischen Evaluierung von Domatinostat im neoadjuvanten Setting beim Urothelkarzinom pressetext.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressetext.com Daily Mail and Mail on Sunday newspapers.